After participating
in this activity, participants should be able to:
 | Incorporate key recommendations from the K/DOQI guidelines into nephrology practice | | Assess the risks of cardiovascular disease in chronic kidney disease patients | | Evaluate safety issues surrounding the management of iron deficiency anemia |
Garabed Eknoyan,
M.D.
Professor of Medicine
Section of Nephrology
Baylor College of Medicine
Houston, TX
Mark Sarnak,
M.D.
Attending Physician
Division of Nephrology
New England Medical Center
Boston, MA
Steven Fishbane, M.D.
Associate Chairman
Department of Medicine
Winthrop-University Hospital
Mineola, NY
| | |
 |
|
ACCREDITATION / DESIGNATION
STATEMENT(S) : |
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the sponsorship of the Medical Education Resources, Inc.
Medical Education Resources, Inc. is accredited by the ACCME to sponsor
continuing medical education for physicians and takes responsibility for the content,
quality, and scientific integrity of this CME activity.
Medical Education
Resources, Inc. designates this educational activity for a maximum of 1.5 hours
in Category 1 credit toward the AMA Physician's Recognition Award. Each physician
should claim only those hours of credit that he/she actually spent in the educational
activity.
|
INSTRUCTIONS FOR CME CREDIT : |
To earn CME credit
for viewing the lectures, please print and complete the CME Posttest questions
and return with the completed Evaluation Form to Medical Education Resources,
Inc. via fax at (303) 798-5731 or mail at 1500 West Canal Court, Suite 500, Littleton,
Colorado 80120-5617.
|
CE for this program has expired.
TARGET AUDIENCE : |
This
program is designed for clinicians who are involved in the care of chronic renal
insufficiency
|
FACULTY
DISCLOSURE STATEMENTS : | All
faculty participating in continuing medical education programs are expected to
disclose to the program audience any real or apparent conflict of interest related
to the subject under discussion. The faculty disclosure information is as follows:
Garabed Eknoyan, M.D., has received grants/research support from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and is a consultant for Amgen and Sigma Tau.
Mark Sarnak, M.D., has received grants/research support from Amgen.
Steven Fishbane,
M.D., has received grants/research support from and is a consultant and speakers' bureay participant for Watson Pharma, Inc.
|
DISCLOSURE OF UNLABELED USE ASN/HDCN (if applicable): |
This educational
activity contains discussion of published and/or investigational uses of agents
that are not indicated by FDA. Medical Education Resources, ASN, HDCN do
not recommend the use of any agent outside of the labeled indications. Please
refer to the official prescribing information for each product for discussion
of approved indications, contraindications and warnings.
All
of the agents overviewed in this virtual symposium will be discussed in the context
of uses for which they have not been approved by the FDA. | |
